Want to see RVMD full AI Analyst Report?
RVMD Stock Chart & Stats
$148.63
$0.52(1.17%)
At close: 4:00 PM EST
$148.63
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$34.00 - $193.83
Previous CloseN/A
Volume180.68K
Average Volume (3M)3.22M
Market Cap
$39.73B
Enterprise Value$33.54B
Total Cash (Recent Filing)$1.91B
Total Debt (Recent Filing)$437.27M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 12, 2026EPS Estimate
-1.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.11
Shares Outstanding212,596,470
10 Day Avg. Volume2,382,152
30 Day Avg. Volume3,224,835
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.63K
Enterprise Value/Ebitda-25.43
Forecast
1Y Price Target
$199.24Price Target Upside34.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-7.95
Revenue Forecast (FY)$105.11M
Bulls Say, Bears Say
Bulls Say
Transformative Phase III EfficacyA convincing Phase III OS benefit (60% reduction in risk of death and median OS >1 year) represents a durable, practice‑changing clinical outcome. This materially increases the likelihood of regulatory filings, label value, and broader adoption, underpinning long‑term commercial and strategic optionality.
Robust Pro Forma Cash RunwayA roughly $4.0 billion pro forma cash position provides sustained funding to complete registrational programs, scale manufacturing and commercial prep, and absorb trial delays. This materially reduces near‑term financing risk and enables strategic flexibility across multiple pipeline assets over the next 2–6 months.
Commercial Launch PreparednessEstablishing U.S. field teams and regional leadership ahead of approvals is a durable strategic asset. It shortens time‑to‑market, supports payer and access negotiations, and preserves first‑mover advantages in priority markets, improving odds of an effective commercial rollout post‑approval.
Bears Say
Zero Revenue And Widening LossesThe absence of product revenue and large, expanding net losses mean the company remains commercially immature and depends on milestones, collaborations, and financing. Persistent negative ROE and cash erosion could force program reprioritization or dilution if approvals or launches are delayed.
Heavy, Worsening Cash BurnOperating and free cash flow deficits have accelerated materially, creating a structural funding drain. Even with current cash, sustained burn will necessitate financing, program cuts, or slower commercialization pacing, constraining strategic optionality and increasing long‑term dilution risk.
Rising Operating Expenses And Stock CompensationMaterial increases in GAAP operating expense guidance and stock‑based compensation raise the company's fixed cost base and normalize higher cash needs. Elevated compensation and op expense guidance can persistently compress future margins and heighten the need for capital, pressuring shareholder dilution and planning flexibility.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines, Inc.’s price range in the past 12 months?
Revolution Medicines, Inc. lowest stock price was $34.00 and its highest was $193.82 in the past 12 months.
What is Revolution Medicines, Inc.’s market cap?
Revolution Medicines, Inc.’s market cap is $39.73B.
When is Revolution Medicines, Inc.’s upcoming earnings report date?
Revolution Medicines, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 29 days.
How were Revolution Medicines, Inc.’s earnings last quarter?
Revolution Medicines, Inc. released its earnings results on May 06, 2026. The company reported -$2.29 earnings per share for the quarter, missing the consensus estimate of -$1.836 by -$0.454.
Is Revolution Medicines, Inc. overvalued?
According to Wall Street analysts Revolution Medicines, Inc.’s price is currently Undervalued.
Does Revolution Medicines, Inc. pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
What is Revolution Medicines, Inc.’s EPS estimate?
Revolution Medicines, Inc.’s EPS estimate is -1.96.
How many shares outstanding does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has 212,596,470 shares outstanding.
What happened to Revolution Medicines, Inc.’s price movement after its last earnings report?
Revolution Medicines, Inc. reported an EPS of -$2.29 in its last earnings report, missing expectations of -$1.836. Following the earnings report the stock price went down -5.666%.
Which hedge fund is a major shareholder of Revolution Medicines, Inc.?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$199.24 (34.05% Upside)
$199.24 (34.05% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 808.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
385.40%
12-Months-Change
Fundamentals
Return on Equity
-83.22%
Trailing 12-Months
Asset Growth
-4.72%
Trailing 12-Months
Company Description
Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
RVMD Stock 12 Month Forecast
Average Price Target
$199.24
▲(34.05% Upside)
Technical Analysis
Ownership Overview
2.11% Insiders
18.40% Mutual Funds
0.28% Other Institutional Investors
64.67% Public Companies and Individual Investors